What is One Drop?
Founded in 2015 and headquartered in New York City, One Drop leverages mobile computing and advanced data science to provide comprehensive diabetes management tools. The platform enables users to meticulously log daily activities, including food intake, insulin levels, and exercise routines. By analyzing these inputs, consumers gain critical insights into the intricate relationships between their lifestyle choices and glucose levels, empowering them to make more informed health decisions. One Drop's approach positions it as a key player in the evolving landscape of personalized health technology.
How much funding has One Drop raised?
One Drop has raised a total of $154.4M across 6 funding rounds:
Angel/Seed
$1M
Series A
$8.6M
Private Equity
$6.1M
Series B
$40M
Series C
$34.7M
Corporate Investment
$64M
Angel/Seed (2015): $1M, investors not publicly disclosed
Series A (2015): $8.6M led by Launch, Neulogy Ventures, RRE Ventures LLC., Box Group, and Capital Factory companies
Private Equity (2017): $6.1M, investors not publicly disclosed
Series B (2019): $40M featuring Bayer
Series C (2020): $34.7M backed by Bayer
Corporate Investment (2020): $64M with participation from Bayer
Key Investors in One Drop
Bayer
Bayer is a global enterprise focused on life sciences, with significant operations in healthcare and nutrition. Their investment in One Drop aligns with their mission to support efforts in overcoming major global health challenges through innovative solutions.
Neulogy Ventures
Neulogy Ventures is a venture capital firm specializing in early-stage technology companies, providing funding and strategic support to innovative startups with high growth potential.
RRE Ventures LLC.
RRE Ventures is a venture capital firm committed to partnering with founders at critical business stages, investing in diverse startups with a focus on long-term growth and entrepreneurial success.
What's next for One Drop?
The substantial enterprise-level capital infusion, particularly the recent strategic investment, signals One Drop's transition into a scaling phase. This financing is poised to accelerate product development, enhance data analytics capabilities, and broaden market reach. Strategic partnerships, potentially with healthcare providers or pharmaceutical companies like Bayer, are likely to be a focus, aiming to integrate One Drop's platform more deeply into existing healthcare ecosystems. The company's continued emphasis on data science and user engagement suggests a trajectory towards becoming a leading digital health solution for chronic disease management.
See full One Drop company page
